Amylyx Pharmaceuticals, Inc.
AMLX
Rangering i aksjer
#4574
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Aksjekurs
$26.82
Markedsverdi
$3.37B
Endring (1 dag)
1.82%
Endring (1 år)
79.40%
Land
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
EPS for Amylyx Pharmaceuticals, Inc. (AMLX)
EPS per June 2026 TTM: $-1.41
Ifølge de siste økonomiske rapportene og aksjekursen til Amylyx Pharmaceuticals, Inc. er selskapets nåværende EPS (TTM) $-1.41. Ved slutten av 2023 hadde selskapet en EPS på $0.73, en økning sammenlignet med EPS-en i 2022 som var $-2.98.
EPS-historikk for Amylyx Pharmaceuticals, Inc. fra 2019 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
